Pfizer won’t apply for COVID-19 vaccine emergency authorisation until after US election, CEO says

October 19, 2020
Sales and Marketing COVID-19, Pfizer, US, Vaccine

The Chief Executive Officer of Pfizer has said that the company will now submit their vaccine for FDA Emergency Use …

brexit-hintergrund_web

UK life sciences industry does not want no-deal Brexit, says ABPI Chief

October 19, 2020
Sales and Marketing ABPI, EU, UK, brexit, pharma

Prime Minister Boris Johnson’s sudden change of position that the UK is now expecting a no-deal scenario with the European …

sanofi_hq__boetie_hall_web

Sanofi’s Dupixent chalks up CHMP recommendation for paediatric severe atopic dermatitis

October 19, 2020
Sales and Marketing Dupixent, EMA, Sanofi, atopic dermatitis

Sanofi’s interleukin-4 and -13 inhibitor Dupixent (dupilumab) has been given the recommendation of the European Medicines Agency’s Committee for Medicinal …

janssen_latest_logo_on_sign

CHMP recommendation for Janssen’s Tremfya in active psoriatic arthritis

October 19, 2020
Sales and Marketing CHMP, EMA, Janssen, Tremfya

Janssen’s interleukin (IL)-23 inhibitor Tremfya (guselkumab) has scored a recommendation from the EMA’s Committee for Medicinal Products for Human Use …

FDA approves Venclexta combo in acute myeloid leukaemia, despite it missing main study goal

October 19, 2020
Sales and Marketing AbbVie, FDA, Roche, Venclexta, pharma

The FDA has given approval to AbbVie and Roche’s jointly-developed BCL-2 inhibitor Venclexta (venetoclax) in combination with azacitidine, decitabine, or low-dose …

nice_new_london_office_internal_3_web

NICE approves Sanofi’s Sarclisa combo for relapsed/refractory multiple myeloma

October 16, 2020
Medical Communications, Sales and Marketing NICE, Sanofi, Sarclisa, multiple myeloma

Sanofi’s Sarclisa (isatuximab) has secured a recommendation from NICE for routine use on the NHS in England and Wales as …

shutterstock

Gilead’s remdesivir and three other repurposed drugs have no impact on COVID-19 mortality, WHO study finds

October 16, 2020
Medical Communications, Research and Development COVID-19, pharma, remdesivir

Gilead’s antiviral therapy remdesivir has emerged as one of the most promising drugs to treat COVID-19 infections, but recent studies …

the_stethoscope_peru

Five-year-old girl that was part of Lysogene’s gene therapy clinical trial dies

October 16, 2020
Medical Communications

A five-year-old girl had died while taking part in Lysogene’s clinical trial investigating its gene therapy. The child was suffering …

covid_cell_1

‘Long COVID’ could be taking four different forms

October 16, 2020
Medical Communications coronavirus, covid symptoms, long covid, symptoms

People experiencing chronic illnesses after COVID-19 infections could be suffering from one of four separate conditions, according to new research. …

top_10_image_2

Top Ten most popular articles on Pharmafile.com this week

October 16, 2020
Medical Communications COVID, herd immunity, top ten, top ten articles

The top ten news stories this week focus on herd immunity, as the Director of the World Health Organization has …

piccadilly_circus_station_during_london_covid-19_lockdown

80 researchers argue COVID-19 herd immunity strategy is a “dangerous fallacy” in open letter

October 15, 2020
Medical Communications, Research and Development, Sales and Marketing COVID-19

A group of 80 researchers have lent their signatures to an open letter published in the The Lancet under the …

Scottish Medicines Consortium gives go-ahead for Novartis’ Mayzent in secondary progressive multiple sclerosis

October 15, 2020
Sales and Marketing Mayzent, Novartis, Scotland

Novartis’ Mayzent (siponimod) has been approved by the Scottish Medicines Consortium in the treatment of secondary progressive multiple sclerosis (SPMS) …

NICE recommends siponimod for treating secondary progressive MS

October 15, 2020
Medical Communications

The National Institute for Health and Care Excellence (NICE) has issued draft guidance recommending siponimod for treating secondary progressive multiple …

800px-who_in_ppe

FDA approves Regeneron’s antibody Ebola treatment

October 15, 2020
Research and Development Ebola, ebola antibody., ebola treatment

The FDA has approved Regeneron’s antibody drug inmazeb for treating Ebola. The treatment works through targeting the glycoprotein on the …

800px-roberto_fico_in_the_russian_state_duma_2019-03-05_03

Russia gives regulatory approval to second COVID-19 vaccine after early clinical trials

October 15, 2020
Research and Development COVID Vaccine, Vaccine, coronavirus vaccine

Russian President Vladimir Putin announced on Wednesday that regulators had given approval to a second coronavirus vaccine. This new vaccine …

450px-flag_of_scotland

Scottish Medicines Consortium approves Revlimid for two groups of blood cancer patients

October 14, 2020
Research and Development Revlimid, SMC

The Scottish Medicines Consortium (SMC) has accepted Revlimid (lenalidomide) for routine use on NHS Scotland for patients with multiple myeloma …

800px-eli_lilly_corporate_center_indianapolis_indiana_usa_1

Eli Lilly COVID-19 antibody therapy trial paused over safety concerns

October 14, 2020
Research and Development COVID, Eli Lilly, coronavirus

Eli Lilly has stopped enrolling volunteers in clinical trials of its antibody treatment for the novel coronavirus over safety concerns.  …

pxfuel

British man suffers from permanent hearing damage after contracting COVID-19

October 14, 2020
Research and Development COVID-19, pharma

A 45-year-old man in the UK has been left with permanent hearing damage after being infected with the novel coronavirus, …

shutterstock_512649

Johnson & Johnson to contribute a further $1 billion to US opioid settlement

October 14, 2020
Research and Development, Sales and Marketing J&J, JJ, opioid crisis, opioids, pharma

Johnson & Johnson will pay another $1 billion to settle lawsuits alleging it fuelled the opioid crisis in the US. …

covid_cell_1

Pharmafile.com’s weekly COVID-19 news round-up

October 14, 2020
Research and Development COVID-19, coronavirus, covid news, pandemic, weekly roundup

The COVID-19 news this week focuses on FDA authorisations, with Eli Lilly seeking Emergency Use Authorization (EUA) from the FDA …

The Gateway to Local Adoption Series

Latest content